Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: natalizumab
INDICATION: Multiple sclerosis
DATE: 29/09/2023
STATUS: Authorized
MORE INFORMATION
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
SUBSCRIBE
